The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

This expansion of the addressable market underscores the company’s continued growth potential in its core therapeutic area. Vertex’s financial performance has been robust, with the company raising its ...

This expansion of the addressable market underscores the company’s continued growth potential in its core therapeutic area. Vertex’s financial performance has been robust, with the company ...

The company’s 2024 performance was solid, with TRIKAFTA/KAFTRIO generating >$10bn revenues, and 2025 guidance suggesting continued growth despite some challenges. Vertex's diversification ...

The total addressable market (TAM) for Vertex’s solutions is estimated at $30 billion, with current adoption rates below 10%. This vast untapped market presents substantial growth opportunities for ...

Looking ahead, Vertex has provided guidance that suggests continued growth. For the fourth quarter of 2024, the company expects adjusted EBITDA of $33.0 million to $37.0 million on revenue of $175 ...

The capital infusion will accelerate the company’s growth and market expansion in India and internationally ... in its Series B round of funding, led by Vertex Ventures. Fireside Ventures also ...

We recently published a list of 13 High Growth Large Cap Stocks ... (see more details here). Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotech company dedicated to developing ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

a price-to-earnings-growth ratio of 6.66 and a beta of 0.87. Vertex (NASDAQ:VERX – Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ...